Gene Manipulation In Human Embryos Provokes Ethical Questions
By Rahel Gebreyes,
HuffPost Live
| 11. 17. 2015
[cites CGS' Marcy Darnovsky]
Untitled Document
A team of Chinese scientists raised eyebrows in April when they modified the genetic code of human embryos to correct the gene defect that causes the hereditary blood disease beta-thalassemia. Now, many researchers and ethicists fear that the technology used to make those manipulations might one day be "exploited for non-therapeutic modifications" such as selecting for intelligence and physical appearance.
While gene editing technology may offer serious health opportunities, it also poses ethical questions, especially if scientists use it for reasons other than preventing illness or diseases, according to Dr. Marcy Darnovsky, executive director of the Center for Genetics and Society.
"Using gene editing on human embryos for reproduction -- that's not really even a medical approach. That's not treating anybody who is sick. That's creating new human beings," Darnovsky told HuffPost Live's Josh Zepps in a video segment (above) on Monday.
As she explained, gene-modification skeptics have raised a number of objections to the budding technology. Darnovsky said:
"There are totally secular objections to it -- having to do with the safety, having to do with the fact...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...